Overview of emerging pharmacologic agents for acute heart failure syndromes. - sprookjes - yvandenbroek - TriplyDB

Overview of emerging pharmacologic agents for acute heart failure syndromes.

Overview of emerging pharmacologic agents for acute heart failure syndromes.

http://www.wikidata.org/entity/Q37086309

about

Gene-disease network analysis reveals functional modules in mendelian, complex and environmental diseases Agents with inotropic properties for the management of acute heart failure syndromes. Traditional agents and beyond Protective effect of resveratrol against pressure overload-induced heart failure.Dyspnoea and worsening heart failure in patients with acute heart failure: results from the Pre-RELAX-AHF study.International variations in the clinical, diagnostic, and treatment characteristics of emergency department patients with acute heart failure syndromes.The role of correction of anaemia in patients with congestive heart failure: a short review.Overview of emerging pharmacotherapy in chronic heart failure.Heart failure burden and therapy.Assessing and grading congestion in acute heart failure: a scientific statement from the acute heart failure committee of the heart failure association of the European Society of Cardiology and endorsed by the European Society of Intensive Care Medi Current management and future directions for the treatment of patients hospitalized for heart failure with low blood pressure.Heart failure: novel therapeutic approaches.Early dyspnoea relief in acute heart failure: prevalence, association with mortality, and effect of rolofylline in the PROTECT Study.Rationale and design of the multicentre, randomized, double-blind, placebo-controlled Aliskiren Trial on Acute Heart Failure Outcomes (ASTRONAUT).Chronic istaroxime improves cardiac function and heart rate variability in cardiomyopathic hamsters.

P2860

Q21135363-253F5309-0F5C-4394-BAD6-9FFE74E31E49 Q24645066-124EBBC1-2F72-49D9-B663-49B56187D014 Q33723046-810C3C1E-D29E-43DF-BF1E-B67A3B0CCEB6 Q34148325-84ABF8E5-A849-4481-8956-0D8D29D8FA7E Q34308342-DCA802E1-CE36-4BCE-9D55-F78327430598 Q37243581-D8232768-AE84-4C92-9CAA-74028F7C2ECD Q37552943-46D5700A-62B8-4E86-9EB2-1C67A87FD42B Q37622587-756C3962-EAFC-4C2F-B73F-17512F2AD21B Q37721628-2DBC3213-648D-42E5-9068-DF7DAB6D437C Q38009708-46C0B0AB-1804-4290-A56B-B702AEF3442B Q38376055-D7A648F6-40F4-4E91-8963-1524A8A286D1 Q39269611-7512B209-B06B-49E0-BDF7-5F4D52DB25AB Q43534981-16132607-96F8-4F9B-9649-1EB396438D36 Q51769776-AA4D79F3-141E-4208-A976-4CE73934473D

P2860

Overview of emerging pharmacologic agents for acute heart failure syndromes.

http://www.wikidata.org/entity/Q37086309

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on February 2008

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Overview of emerging pharmacologic agents for acute heart failure syndromes.

@en

Overview of emerging pharmacologic agents for acute heart failure syndromes.

@nl

type

label

Overview of emerging pharmacologic agents for acute heart failure syndromes.

@en

Overview of emerging pharmacologic agents for acute heart failure syndromes.

@nl

prefLabel

Overview of emerging pharmacologic agents for acute heart failure syndromes.

@en

Overview of emerging pharmacologic agents for acute heart failure syndromes.

@nl

P1433

Q37086309-9F1830A2-2D78-4CE2-A723-AEF28A9122BF

P1476

Q37086309-C8384265-E294-4685-9952-DD39C8EE108A

P2093

Q37086309-1091FAFE-2AEB-426B-B43E-6B1115A36971

Q37086309-436601F4-B5D5-4C96-9EBC-3420FA0A8DE8

Q37086309-53BF0AAF-2D4D-4FA2-8BF4-B257EB909C9F

Q37086309-784A2D44-86FD-43B8-A2C9-D425CA5BF17D

Q37086309-8B3D9DEC-FC45-481F-8A8B-1A628B9F3A76

Q37086309-A6A01C79-9E25-492C-8BCF-8AAB7F53BD88

Q37086309-BEE49218-5C46-48BB-B5CD-2B2975DD7330

P2860

Q37086309-0736C147-80CD-4BCC-A5EE-0872A990E4C4

Q37086309-09D8812F-F3ED-4275-BD93-D4345175C391

Q37086309-0A0D7FA5-B018-4621-B31C-CBDAE2153DEA

Q37086309-0AEAE0C2-E02F-4AC6-B12B-0B8D5B7DC578

Q37086309-0DE86EEE-42B9-4117-B4A9-70BED25C10EA

Q37086309-1DA698BD-6604-443C-A8A9-5E8E3527E760

Q37086309-1EDC3325-5C9C-4E8E-A2BA-45FC6B882D4A

Q37086309-2BC65372-94D7-498B-9752-1CC74382E0ED

Q37086309-356E399B-1F69-4776-AE6C-01F9A5CF0BE1

Q37086309-390A7786-A853-42AC-9AF4-E4D5513A0CA6

P304

Q37086309-D9FDE67B-6B5A-4712-9BA0-380744F1ED7E

P31

Q37086309-649C7A7A-3F0D-4DD2-A076-66B38BA6D044

P356

Q37086309-D70A8853-97F8-4B74-973F-0219955944FB

P433

Q37086309-4AC7D46C-8202-4CCD-A91C-C5A93ECD545F

P478

Q37086309-E2FE5225-ABED-468D-B18B-7F07540C4C85

P50

Q37086309-2DF0E7A3-A0C2-4249-94F5-78A78A0A0221

Q37086309-37C9F20E-6C15-4D09-B76D-30DBA9872CE0

Q37086309-715DCBCE-48C4-44A0-B8C7-C5DD9FCC1947

Q37086309-71B6FF98-64AE-4B19-9EF2-E05416D00AF4

Q37086309-A060A5D3-98D7-4CAE-B585-EF8D95460853

P577

Q37086309-122547E1-7E48-4538-9145-6C03E7F93F4C

P698

Q37086309-AC4A37C4-06A2-4920-BF66-460EDB8F05C1

P921

Q37086309-44D96087-DE28-4728-B1A3-4BFFDED6EF30

Q37086309-A81344C6-2F07-4E10-860C-FEBFEDBD1189

P356

J.EJHEART.2008.01.002

P1433

European Journal of Heart Failure

P1476

Overview of emerging pharmacologic agents for acute heart failure syndromes.

@en

P2093

Adriaan A Voors

http://www.w3.org/2001/XMLSchema#string

Ali El-Banayosy

http://www.w3.org/2001/XMLSchema#string

Andrew Rhodes

http://www.w3.org/2001/XMLSchema#string

John T Parissis

http://www.w3.org/2001/XMLSchema#string

Leonardo De Luca

http://www.w3.org/2001/XMLSchema#string

Markku Nieminen

http://www.w3.org/2001/XMLSchema#string

Michael Böhm

http://www.w3.org/2001/XMLSchema#string

P2860

Vasopressin V2-receptor blockade with tolvaptan in patients with chronic heart failure: results from a double-blind, randomized trial

BG9719 (CVT-124), an A1 adenosine receptor antagonist, protects against the decline in renal function observed with diuretic therapy

The renal urodilatin system: clinical implications

Effects of multiple oral doses of an A1 adenosine antagonist, BG9928, in patients with heart failure: results of a placebo-controlled, dose-escalation study

Short-term risk of death after treatment with nesiritide for decompensated heart failure: a pooled analysis of randomized controlled trials

The effects of KW-3902, an adenosine A1-receptor antagonist,on diuresis and renal function in patients with acute decompensated heart failure and renal impairment or diuretic resistance

Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: a randomized controlled trial

Risk of death associated with nesiritide in patients with acutely decompensated heart failure

Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE Randomized Trial

Perhexiline maleate and peripheral neuropathy

P304

201-213

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.EJHEART.2008.01.002

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

10

http://www.w3.org/2001/XMLSchema#string

P50

Kenneth Dickstein

Mihai Gheorghiade

Gerasimos Filippatos

Alexandre Mebazaa

P577

2008-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

18279775

http://www.w3.org/2001/XMLSchema#string

P921